MNMD Stock Overview
A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mind Medicine (MindMed) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.16 |
| 52 Week High | US$12.22 |
| 52 Week Low | US$3.49 |
| Beta | 2.38 |
| 1 Month Change | -5.29% |
| 3 Month Change | 21.98% |
| 1 Year Change | 98.89% |
| 3 Year Change | -71.76% |
| 5 Year Change | n/a |
| Change since IPO | -17.79% |
Recent News & Updates
Recent updates
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Nov 04Psychedelic Stocks: Focus On Their Cash
Aug 15MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Jun 05Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20MindMed regains compliance with Nasdaq's minimum bid price listing requirement
Sep 14MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value
Sep 04Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Aug 26Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder
Aug 24MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps
Aug 18Shareholder Returns
| MNMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -2.4% |
| 1Y | 98.9% | 7.9% | 23.4% |
Return vs Industry: MNMD exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: MNMD exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| MNMD volatility | |
|---|---|
| MNMD Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MNMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MNMD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Rob Barrow | www.mindmed.co |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc. Fundamentals Summary
| MNMD fundamental statistics | |
|---|---|
| Market cap | US$525.05m |
| Earnings (TTM) | -US$97.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs MNMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$97.80m |
| Earnings | -US$97.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 9.3% |
How did MNMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 15:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mind Medicine (MindMed) Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Tania Armstrong-Whitworth | Canaccord Genuity |